PubMed Health⌕ Search

Biomedical subjects

D Ackery

Publications and source records attributed to D Ackery.

At least 19 recordsLinked to original sources
PubMed1993

Radionuclide-targeted therapy for the management of metastatic bone pain.

Strontium-89 is preferentially taken up at sites of increased bone mineral turnover, its uptake adjacent to malignant metastases being up to five times greater than for normal bone. Strontium-89 is also selectively retained in bone adjacent to metastatic sites. The initial therapeutic ratio is therefore good and increases with time. The pharmacokinetics of strontium-89 thus favor the objective of achieving a clinically effective beta radiation dose to tumor deposits while minimizing radiation exposure to healthy tissue. Clinical studies show that 150 MBq [corrected] strontium-89 can relieve bone pain in up to 80% of patients with prostatic metastases. Greater activities do not appear to increase this level of response. Once a response has been achieved, strontium-89 therapy can be repeated when pain recurs. Although hematologic toxicity at this dosage is low, strontium-89 should not be given to patients with evidence of significant bone marrow depression. With this precaution, no serious toxicity has been encountered when the agent is administered at the recommended doses.

Bone Neoplasms↗
PubMed1992

Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.

PURPOSE: The goal of this study was to evaluate the toxicity of iodine 131 metaiodobenzylguanidine (mIBG) in metastatic neuroblastoma. PATIENTS AND METHODS: A multicenter phase I study of 131I mIBG has been undertaken by the United Kingdom Children's Cancer Study Group (UKCCSG) in children with advanced chemoresistant neuroblastoma. Activity prescription was based on a prescribed whole-body radiation dose, which was established for individual patients by performing an initial tracer investigation with 75 MBq of 131I mIBG. An activity was derived from this pharmacokinetic study that would deliver an initial whole-body-absorbed radiation dose of 1 Gy. Subsequent dose escalations were based on observed toxicity. RESULTS: Twenty-five patients, aged 1 to 10 years, were treated with prescribed whole-body dose levels of 1.0 Gy (n = 2), 2.0 Gy (n = 13), and 2.5 Gy (n = 10). This necessitated administration of 2.4 to 12.1 GBq of activity. Hematologic, hepatic, kidney, and adrenal toxicity were observed, with bone marrow suppression being the principal dose-limiting toxicity. Bone marrow toxicity increased with prescribed whole-body-absorbed radiation dose, with 80% of patients developing grade 3 or 4 thrombocytopenia at a prescribed whole-body radiation dose of 2.5 Gy. Objective evidence of tumor response was seen in soft tissue (primary or nodal disease), bone, and bone marrow, with an overall response rate of 33% (partial response, n = 8; static disease, n = 9; progressive disease, n = 7). CONCLUSIONS: This study has established an effective method of activity prescription that predicts subsequent toxicity, with the maximally tolerated dose being sufficient activity to deliver a whole-body-absorbed radiation dose of 2.5 Gy. The objective response rate is comparable to other single agents in chemoresistant neuroblastoma and suggests that 131I mIBG may be a useful method for targeting radiotherapy in metastatic neuroblastoma.

3-Iodobenzylguanidine↗
PubMed1991

Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study.

In 1987, the United Kingdom Children's Cancer Study Group (UKCCSG) set up a multi-centre study to investigate the toxicity of iodine 131 metaiodobenzylguanidine (mIBG) in the treatment of resistant neuroblastoma. Since December 1987, 25 children suffering from neuroblastoma have been treated with 131I-mIBG at six UK centres. All centres followed standardised physics and clinical protocols to provide consistent toxicity and dosimetry data. These protocols describe the methods employed for both the tracer study using 131I-mIBG and the subsequent therapy. Whole-body dosimetry calculations were performed on data from the tracer study. The activity administered for therapy was the amount predicted to deliver a predefined whole-body dose. Estimates of doses delivered to various organs during treatment are given in Table 1.

3-Iodobenzylguanidine↗
PubMed1990

Distribution of bony metastases in prostatic carcinoma.

Fifty-five prostate cancer and 55 breast cancer patients with positive bone scintigrams were studied. The pattern of spread in the axial skeleton and pelvis showed differences between the 2 groups. This difference was not related primarily to bone volume at the site of metastasis. The difference in distribution of bony metastases between breast and prostate is explained by our knowledge of Batson's vertebral venous plexus.

Bone Neoplasms↗
PubMed1989

A gamma camera method to monitor the use of degradable starch microspheres in hepatic arterial chemotherapy.

A gamma camera method to quantify the haemodynamic effects of degradable starch microspheres (DSM) in intra arterial hepatic therapy is described. Results are presented from ten patients with colorectal liver metastases. Intra hepatic arterio venous shunting was present in 1 patient prior to DSM and in 2 subjects after three 300 mg DSM fractions. DSM reduced the rate of flow of injectate to the lung in all cases. Conversely, an increased rate of flow of injectate to gut or spleen occurred with 300 mg fractions of DSM in 7/9 cases. Lower dose DSM fractions are indicated. At 2-3 min after DSM injection the mean fraction of the activity retained in the liver was 0.22. A DSM induced enhancement of tumour relative to normal tissue perfusion was obtained in four out of five tumour regions identified. All indices showed a wide variation between patients and between individual DSM doses, and the high incidence of extra hepatic shunting confirms the need for monitoring when using intra arterial microspheres.

Antineoplastic Agents↗
PubMed1988

Ventilation/perfusion mismatch in interstitial fibrosis.

Regional pulmonary perfusion defects unmatched by ventilation loss, occurring in a patient with proven interstitial lung fibrosis, is reported. This condition is not a widely recognized cause of ventilation/perfusion mismatch.

Aged↗
PubMed1987

Measurement of glomerular filtration rate with 99mTc-DTPA: a comparison of gamma camera methods.

A comparison has been made between three gamma camera methods for estimation of glomerular filtration rate (GFR) using 99mTc-DTPA in a group of 27 patients with widely different renal function. Plasma clearance of 99mTc-DTPA by multiple blood sampling was used as the reference. Percentage uptake of chelate in the bladder and kidneys at 20 min after injection gave the lowest standard error of 8.0 ml/min. Techniques using early uptake of isotope in the kidneys at 2 min after injection gave less accurate estimates. Correction for the vascular activity in the renal region of interest improved the results for the 2 min uptake technique. Gamma camera techniques provide rapid estimates of GFR which are less accurate than those obtained by plasma clearance of labelled chelate.

Glomerular Filtration Rate↗
PubMed1987

Longitudinal assessment of glomerular filtration rate by gamma camera and portable external detector.

Noninvasive isotope chelate methods to assess glomerular filtration rate (GFR) are less accurate than blood sampling. However, some measurement errors would be expected to be constant for an individual, and repeat estimations may be less variable. In 18 patients, estimates of GFR were obtained by 2 gamma camera techniques and a portable external detector at a mean interval of 1 year, to assess accuracy in predicting a change of GFR. Errors in these techniques were not significantly better than those predicted from two independent estimates. Most GFR measurement error for noninvasive methods appears to be random.

Adult↗
PubMed1987

Measurement of glomerular filtration rate with a portable cadmium telluride detector.

The plasma clearance rate constant of 99Tcm-DTPA was measured with a portable cadmium telluride detector over anterior chest wall and lateral leg sites to obtain an empirical estimate of glomerular filtration rate (GFR). Thirteen patients with a range of renal dysfunction were studied to compare the accuracy of the estimates over various time periods compared to GFR estimated from plasma sampling. The chest site was more accurate for GFR assessment over all time periods assessed up to 4 h following injection. The clearance rate constants obtained up to 1 h after injection from the chest site were not significantly less accurate then those from later time periods.

Cadmium↗
PubMed1986

Radioiodinated iodobenzylguanidines for diagnosis and therapy.

Radiolabelled meta-iodobenzylguanidine has been one of the most successful of recent radiopharmaceuticals. In the short period of five years it has been shown to have high diagnostic sensitivity and specificity for many tumours of neuroectodermal origin. Furthermore its excellent concentration in many malignant tumours of this type offers a novel alternative treatment to those available at present.

3-Iodobenzylguanidine↗
PubMed1986

Does radiolabelled diphosphonate retention reflect bone metabolism in the elderly?

The 24-h whole-body retention of diphosphonates (WBR), a useful measure of bone metabolism in young subjects, was measured in 27 elderly subjects (19 from home and eight in-patients). WBR rose with increasing age (r = 0.55, P less than 0.01) and was negatively correlated with renal function (r = -0.60, P less than 0.01). In five subjects given vitamin D, WBR did not fall. The measurement of WBR in the elderly has to be assessed in the light of an accurate assessment of renal function and so is rarely clinically useful.

Aged↗
PubMed1984

Vitamin B12 absorption after necrotizing enterocolitis.

Resection of the terminal ileum for necrotizing enterocolitis is not uncommon in neonates requiring intensive care in the first weeks of life. They may therefore be at risk of vitamin B12 malabsorption, and later of vitamin B12 deficiency. A method of measuring B12 absorption is described and the results are given. This assessment should be part of the follow up for all these children.

Child↗
PubMed1984

A comparison between the use of a shadow shield whole body counter and an uncollimated gamma camera ain the assessment of the seven-day retention of SeHCAT.

We have compared the 7-day retention of the radioisotope bile salt analogue SeHCAT (75Se-23-selena-25-homotaurocholate), by whole body counting and by uncollimated gamma camera measurement, in phantoms and in 25 patients with inflammatory bowel disease. The results correlate with a linear correlation coefficient of 0.96. An uncollimated gamma camera can be used to assess bile acid malabsorption when a whole body radioactivity monitor is not available.

Colitis, Ulcerative↗
PubMed1982

Disseminated malignant phaeochromocytoma: localisation with iodine-131-labelled meta-iodobenzylguanidine.

Meta-iodobenzylguanidine, a guanethidine analogue, is a newly synthesised substance capable of imaging the adrenal medulla. In a woman in whom phaeochromocytoma has been diagnosed iodine-131-labelled metaiodobenzylguanidine was given intravenously; gamma-camera images showed bilateral adrenal tumours and uptake corresponding to bone and liver metastases. 131I-meta-iodobenzylguanidine is effective in localising phaeochromocytomas, and the technique is safe, specific, and non-invasive.

3-Iodobenzylguanidine↗